Bio-Path HoldingsBPTH -2.13% EV-to-FCF is -8.77 as of Jul. 06, 2026. The stock has 1 warning sign investors should review. Among 330 Biotechnology companies, Bio-Path Holdings ranks worse than 303030% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bio-Path Holdings's Enterprise Value is $2.81 Mil.
Bio-Path Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.32 Mil. Therefore, Bio-Path Holdings's EV-to-FCF for today is -8.77.
The historical rank and industry rank for Bio-Path Holdings's EV-to-FCF or its related term are showing as below:
BPTH'
s EV-to-FCF Range Over the Past 10 Years
Min: -12.99 Med: 0.01 Max: 0.32
Current: -8.77
During the past 13 years, the highest EV-to-FCF of Bio-Path Holdings was 0.32. The lowest was -12.99. And the median was 0.01.
BPTH's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 16.3
vs BPTH: -8.77
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bio-Path Holdings's PE Ratio (TTM) for today is calculated as:
Bio-Path Holdings's share price for today is $0.046.
Bio-Path Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.690.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bio-Path Holdings EV-to-FCF Related Terms
Bio-Path Holdings EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bio-Path Holdings's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bio-Path Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Path Holdings EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bio-Path Holdings's EV-to-FCF falls into.
Bio-Path Holdings's current Enterprise Value is $2.81 Mil.
Bio-Path Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Path Holdings (BPTH) has a EV-to-FCF of -8.77 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bio-Path Holdings and its competitors. According to the industry distribution chart, Bio-Path Holdings ranks #999999 out of 330 companies in the Biotechnology industry.
Is Bio-Path Holdings' EV-to-FCF too high?
Bio-Path Holdings' current EV-to-FCF is -8.77. Based on the distribution chart, Bio-Path Holdings ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bio-Path Holdings' EV-to-FCF compare to VBIO and HEPA?
According to the Biotechnology industry distribution chart, Bio-Path Holdings ranks #999999 out of 330 companies for EV-to-FCF. This places Bio-Path Holdings in the lower half of its industry. The industry median EV-to-FCF is 16.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.30, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bio-Path Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Path Holdings's current EV-to-FCF is -8.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current EV-to-FCF of -8.77. The current EV-to-FCF is -8.77. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current EV-to-FCF is -8.77 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BPTH has been successfully added to your 